Prelude Therapeutics reports Q3 results
Prelude Therapeutics (PRLD) reported Q3 GAAP EPS loss of $0.12, revenue of $5.6M (down 13% Y/Y), and net loss of $12.5M (down 36% Y/Y). R&D expenses fell 32% to $14.8M, while G&A expenses decreased 2% to $5.1M. The company had $142.7M in cash and equivalents, with a runway into Q2 2028.
How this was made

The 30-second read
Why it matters
The earnings miss and revenue decline provide fresh data for traders; the sizable cash position may mitigate immediate risk.
Market read
First‑report earnings for a micro‑cap biotech; likely short‑term price impact.
What to watch
R&D expense down 32% YoY may indicate cost‑cutting or slower program progress.
Background
Prelude Therapeutics issued a press release reporting its Q3 2026 financial results.
Ticker impact
Q3 GAAP EPS loss of $0.12, revenue $5.6M (down 13% YoY), cash $142.7M runway into Q2 2028.
likely downward pressure as investors price the loss and slower revenue growth
The loss per share and revenue decline are new primary data; small‑cap biotech earnings typically move the stock on the day of release.
Market effects
Biotech sector may see modest pullback as a peer reports weaker Q3 results.
U.S. small‑cap biotech investors may adjust exposure.
Limited; impact confined to niche biotech investors.
Counterpoint
Cash runway to 2028 could support a longer‑term upside if pipeline milestones are hit.
Key entities
- companyPrelude Therapeutics Incorporated
Biotech firm reporting Q3 results.
